FDA Encourages Development of Novel Drug Delivery Systems - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Encourages Development of Novel Drug Delivery Systems


Pharmaceutical Technology


Improving reviews

As more complex drug products and delivery systems move through the development pipeline, FDA is revising its application review system to better assess drug quality and manufacturing issues. Nasr's office now includes a manufacturing science branch staffed by pharmaceutical scientists and engineers with expertise in manufacturing and new dosage forms. Under a new process for assessing chemistry, Manufacturing, and controls (CMC) data in new drug applications (NDAs), an ONDQA reviewer completes an initial quality assessment of a new application to identify challenging quality or CMC issues. Such products, including those with innovative delivery systems, are eligible for review by an interdisciplinary team, an approach that Nasr says is now being used for approximately 25% of NDAs. The application for the new inhaled insulin product, for example, involved a team review with expertise in manufacturing, biotech products, and inhaled delivery systems.

For his staff to conduct a more informed application review, Nasr points out that manufacturers must provide more extensive information about drug development and product design than in the past. "We are looking for more information on design and manufacturing," he explains. Documentation about how manufacturing controls can ensure product quality may lead to regulatory flexibility.

Cold-chain challenges

One advantage of some new drug formulations is that they are more temperature stable and do not need to meet rigorous cold chain storage and distribution requirements. Abbott, for example, recently won FDA approval for a new heat-resistant formulation of its HIV drug "Kaletra," which offers major advantages to health agencies and patients around the world. Even though it took the company years of research to develop the more stable product, Abbott now faces challenges in distributing the drug on a low-cost basis to third-world nations in which AIDS is rampant and temperature stability is a major plus (see sidebar "Product improvement wins little praise").

Nearly 10% of drugs and biologics are temperature sensitive, and the development of more biologicals and vaccines is increasing the volume of products requiring controlled temperature-storage conditions. This trend is prompting a reexamination of the diverse regulatory policies that govern cold-chain distribution around the world. Manufacturers find that FDA and other GMP inspectors are issuing citations for inadequate storage and transportation management practices, despite generally vague requirements. Health Canada took the lead this past October by posting new guidelines to ensure proper handling and transport of temperature-sensitive products. The US Pharmacopeia updated its General Chapter ‹1079› about good storage and shipping practices to address the need to prevent temperature excursions. And, the PDA Pharmaceutical Cold Chain Discussion Group prepared a technical report (No. 39) about "Maintaining the Quality of Temperature-Sensitive Medicinal Products Through the Transportation Environment." It proposes standards and validating processes to ensure the quality of products requiring thermally controlled storage and transportation.

FDA relies primarily on GMPs and stability guidances to cover distribution and storage practices and monitoring, but the literature lacks specific requirements for ensuring temperature control. The need to ensure appropriate storage practices and broader government concerns about protecting the nation against bioterrorism and drug diversion have generated a high level of awareness about these issues at CDER's Division of Manufacturing and Product Quality. The office is assessing the need for additional guidance about cold-chain management issues, commented DMPQ Acting Director Nicholas Buhay at a PDA conference about cold chain management in March. Buhay says this topic has become a formal project to review current requirements and weigh the need for additional guidance. FDA does not want to establish new rules for storage and transportation, says Buhay, "unless there is clear value in doing so." One concern is that new policies for documenting distribution or revising product labeling on appropriate storage conditions could generate a wave of manufacturing supplements. The agency currently prefers to set overall requirements for ensuring drug quality, without compelling manufacturers to generate massive amounts of new data for FDA to review.

"The aim of all these initiatives is to prevent drug manufacturing from creating a bottleneck in getting medicines to patients," commented Gottlieb in a recent speech about good manufacturing practices. Gottlieb noted that with more novel drug delivery systems and more complex drugs, it is even more important to address key quality issues and to establish meaningful product specifications. This strategy means moving away from conventional batch processing systems and adopting modern process development and control technologies, as encouraged by FDA's initiative to modernize GMPs for the 21st Century. To continue its progress in this area, FDA plans to issue a final guidance about quality systems this summer and a final report summarizing its risk model for prioritizing sites for manufacturing inspections.

Jill Wechsler is Pharmaceutical Technology's Washington editor, 7715 Rocton Ave., Chevy Chase, MD 20815, tel. 301.656.4634,


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here